Stay updated on ABT-165 Combo vs Bevacizumab Combo in Metastatic CRC Clinical Trial
Sign up to get notified when there's something new on the ABT-165 Combo vs Bevacizumab Combo in Metastatic CRC Clinical Trial page.

Latest updates to the ABT-165 Combo vs Bevacizumab Combo in Metastatic CRC Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedPublication notes under PubMed now state that publications are automatically filled from PubMed, and the footer revision number changed from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check20 days agoChange DetectedRemoved the government funding status notice from the page. This change does not affect the study details or enrollment information.SummaryDifference0.2%

- Check34 days agoChange DetectedNo significant changes were detected; the study arms, outcomes, eligibility, and locations appear unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check63 days agoChange DetectedSignificant update: new operating-status notice and funding-related limitations are added, plus a version bump to v3.2.0; previous v3.1.0 deletion indicates a version upgrade.SummaryDifference3%

- Check70 days agoChange DetectedVersion update: from v3.0.2 to v3.1.0.SummaryDifference0.1%

- Check84 days agoChange DetectedUpdated page revision from v3.0.1 to v3.0.2, signaling a new release with fixes or improvements. The 'Back to Top' link/control was removed, a minor UI change.SummaryDifference0.2%

Stay in the know with updates to ABT-165 Combo vs Bevacizumab Combo in Metastatic CRC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ABT-165 Combo vs Bevacizumab Combo in Metastatic CRC Clinical Trial page.